🔀 A *twist* of fate in tumor evolution? When EMT drivers like TWIST, ZEB1, and Snail rewire cellular identity, cancer cells can gain phenotypic plasticity. 👉 Explore key EMT signatures, pluripotency markers, and “stemness” targets on the #CSTBlog. hubs.ly/Q04ztJm-0

Inflammasome Therapeutics: How the Inflammasome Pathway is Being Targeted to Treat Chronic Diseases - Explore how targeting inflammasome pathways leads to novel therapeutics for chronic diseases on the CST Blog. hubs.ly/Q04BVh0m0

Do you want publication-ready IHC/IF images every time? Join us for our live Applications 101 webinar, See the Signal: Master IHC & IF Staining. Get practical tips and tricks for successful imaging results 📅 Oct 29 | 8:00 AM & 4:00 PM CET  👉 Register: hubs.ly/Q04z8ms40

Huntington's Disease Biomarkers: Key Molecular Targets and Antibody Tools for HD Research - Explore key Huntington's disease biomarkers and validated CST antibodies for studying mHTT, neuronal loss, striatal dysfunction, and neuroinflammation. hubs.ly/Q04Bqsrl0

🧬🔬Trying to identify the epigenetic reprogramming mechanism responsible for the change in gene expression? Analyze epigenetic regulator proteins via chromatin profiling to identify changes in epigenetic signatures across the genome. hubs.ly/Q04g4XRT0

A “pan” western blot-validated antibody might not give you the IHC coverage you need. Learn how our new Pan-Keratin MultiMab® Antibody mix, validated in both applications, enables confident ID of epithelial and tumor cells in your tissue samples. hubs.ly/Q04zt_Y00

Heading to #ELRIGDD26 next week?  Explore CST solutions for spatial biology, immunoassays & antibody conjugation—including SignalStar® Multiplex IHC, chimeric antibodies and validated antibody pairs built for data you can trust.  #DrugDiscovery #SpatialBiology

🏗️🩸Why is tumor vasculature chaotic, disorganized, and characteristically leaky? 👉 Explore the signaling events behind the “angiogenic switch” including markers from key pathways that are activated as part of tumor angiogenesis. hubs.ly/Q04g4QGL0

How the Inflammasome Drives Disease: Tackling Aberrant Inflammasome Signaling - Discover how aberrant inflammasome signaling drives chronic disease and explore CST-validated antibodies to study these non-communicable pathways. hubs.ly/Q04yLcvj0

Identifying key drivers of sustained cellular proliferation is now possible at the single-cell level 📈 InTraSeq™ Single Cell Analysis conjugate antibody cocktails contain key cell growth and viability signaling targets: hubs.ly/Q042ys6v0

Inconsistent ELISA results? Join Dr Christina Theisgen for our live Applications 101 webinar and learn how to build more reliable assays with ELISA kits and matched antibody pairs. 📅 Oct 1 | 8:00 AM & 4:00 PM CEST 👉 Register: hubs.ly/Q04xdx0Z0

EMT is an example of phenotypic plasticity driven by dedifferentiation that can facilitate cancer progression Use CST® IHC-validated antibodies against E-Cadherin and N-Cadherin to determine if the cadherin switch has been activated in your cancer model hubs.ly/Q042ylQd0

An Open Letter Concerning Antibody Data Integrity - Open Letter to the Scientific Community | CST Commitment to Data Integrity hubs.ly/Q04y7J6X0

Why We Have 13,500 Antibodies, Not >100K | Manufacturing Transparency hubs.ly/Q04y3Jzk0

New Webinar Series: Master core lab techniques with CST experts  ● Oct 1 – ELISA  ● Oct 29 – IHC/IF  ● Dec 3 – Flow Cytometry  ● Jan 21 – Western Blotting  Register today: hubs.ly/Q04x76_R0

⚡🔬Planning your next experiment to examine cancer metabolism? Start with the pathways tumors most commonly hijack. 🔗 Explore key metabolic signaling targets, pathways, and antibody tools for Deregulating Cellular Metabolism on the #CSTBlog. hubs.ly/Q04g4MRb0